How is a GRIN2A-related epilepsy-aphasia spectrum condition typically diagnosed?

Diagnosis usually involves a combination of clinical evaluation, electroencephalogram (EEG) to detect abnormal brain activity, especially during slow-wave sleep, and genetic testing to identify specific mutations in the GRIN2A gene.

What are the main treatment approaches for individuals with GRIN2A-related epilepsy-aphasia spectrum disorders?

Treatment primarily focuses on managing seizures with anti-epileptic medications and addressing speech and language difficulties through therapy. The specific medication choice may depend on the type of seizure and the suspected effect of the GRIN2A mutation on receptor function.

GRIN2A gene

The GRIN2A gene encodes a subunit of NMDA receptors, which are critical for nerve cell signaling, brain development, learning, and memory.

Normal Function

The GRIN2A gene provides instructions for making a protein called GluN2A (formerly known as NR2A). This protein is found in nerve cells (neurons) in the brain and spinal cord, including regions involved in speech and language. The GluN2A protein is one component (subunit) of a subset of NMDA receptors. These receptors are glutamate-gated ion channels; when brain chemicals called glutamate and glycine attach to the receptor, a channel opens, allowing positively charged particles (cations) to flow through. This flow generates currents that activate (excite) neurons to send signals in the brain. NMDA receptors are involved in normal brain development, synaptic plasticity, learning, and memory.

Health Conditions Related to Genetic Changes

Epilepsy-aphasia spectrum

More than 50 mutations in the GRIN2A gene have been identified in people with conditions that fall along the epilepsy-aphasia spectrum. This group of conditions is characterized by abnormal electrical activity in the brain, usually during slow-wave sleep; a loss of speech and language skills; and in many cases, recurrent seizures (epilepsy).

Many GRIN2A gene mutations lead to production of a nonfunctional GluN2A protein or prevent the production of any protein at all. Researchers suspect this leads to a reduced number of NMDA receptors containing the GluN2A subunit, causing signaling to occur through other types of NMDA receptors that more easily excite neurons. Other mutations lead to production of abnormal GluN2A proteins that likely alter how the NMDA receptors function, possibly increasing signaling. Excessive activity of neurons can lead to seizures and other abnormal brain activity.

Other disorders

GRIN2A gene mutations have been found in people with neurological disorders that have features similar to epilepsy-aphasia spectrum disorders but lack consistent language problems. These shared features can include recurrent seizures (often rolandic epilepsy), intellectual disability, and developmental delay.

Other Names for This Gene

EPND
GluN2A
glutamate receptor ionotropic, NMDA 2A isoform 1 precursor
glutamate receptor ionotropic, NMDA 2A isoform 2 precursor
glutamate receptor, ionotropic, N-methyl D-aspartate 2A
LKS
N-methyl D-aspartate receptor subtype 2A
N-methyl-D-aspartate receptor channel, subunit epsilon-1
N-methyl-D-aspartate receptor subunit 2A
NMDAR2A
NR2A